SCHOOL
ACUTE LEUKEMIA
Clinical And Biological
www.sohoitaly.it

15 16 17 March 2021

C. Cerchione  N. Daver  A. De La Fuente  E. Jabbour  H. Kantarjian
M. Konopleva  F. Locatelli  G. Martinelli  F. Ravandi

Virtual Event

JOIN US!

@sohoitaly
#SOHOitLEUKEMIA

20 CME (ECM) HEMATOLOGISTS, ONCOLOGISTS, PATHOLOGIST, BIOLOGISTS
SOHO ITALY

SCHOOL

ACUTE LEUKEMIA

Clinical And Biological

15 16 17 March 2021

Virtual Event

Presidents:
Cerchione C, Martinelli G, Kantarjian H

Scientific Board:

Scientific Secretariat:

Big Faculty:
Day 0  

15 March 2021

18.30 - 19.00  Lecture: How I manage Acute Myeloid Leukemia at MD Anderson Cancer Center - H. Kantarjian

19.00 - 19.30  Lecture: How I manage Acute Myeloid Leukemia in Europe - G. Martinelli

19.30 - 20.00  Lecture: How I manage Acute Lymphoblastic Leukemia at MD Anderson Cancer Center - H. Kantarjian

20.00 - 20.30  Lecture: How I manage Acute Lymphoblastic Leukemia in Europe - G. Martinelli

20.30 - 21.00  Lecture: How I manage pediatric Acute Leukemias - F. Locatelli

Day 1  

16 March 2021

Frontal Session

08.30 - 08.50  Opening and introduction to the project: C. Cerchione – G. Martinelli

Acute Lymphoblastic Leukemia
Biology and MRD Session in ALL: G. Martinelli, C. Papayannidis, C. Quintarelli

08.50 - 09.10  Molecular pathogenesis of ALL and new molecular-based potential treatments - A. Ferrari
09.10 - 09.30  Impact of new opportunities in ALL biology - C. Quintarelli
09.30 - 09.50  Importance of MRD in ALL - C. Papayannidis
09.50 - 10.10  Synthetic lethality: what’s new? - A. Ghelli
10.10 - 10.30  break

**Biology Session AML - G. Simonetti, F. Buccisano, G. Rosti**

10.30 - 10.50  AML biology: what’s new? - G. Simonetti
10.50 - 11.10  Molecular Pathogenesis of AML - S. Galimberti
11.10 - 11.30  Importance of MRD assessment and impact on treatment - F. Buccisano

**Clinical Session ALL 1 – G. Martinelli, F. Locatelli, F. Lanza**

11.30 - 11.50  How we manage ALL in daily practice in Europe - G. Martinelli
11.50 - 12.10  Role of monoclonal antibodies in relapsed/refractory - F. Lanza
12.10 - 12.30  Near future of ALL - R. Foà
12.30 - 12.40  Discussion
12.40 - 13.40  Lunch Symposium
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.40 - 14.00</td>
<td>Clinical Session ALL 2 - H. Kantarjian, E. Jabbour, M. Konopleva</td>
</tr>
<tr>
<td></td>
<td>Major differences between Europe and USA in the management of ALL and AML - H. Kantarjian</td>
</tr>
<tr>
<td>14.00 - 14.20</td>
<td>Immunotherapy in adult and elderly ALL - E. Jabbour</td>
</tr>
<tr>
<td>14.20 - 14.40</td>
<td>How I manage Ph-positive ALL - E. Jabbour</td>
</tr>
<tr>
<td>14.40 - 15.00</td>
<td>How I manage Early T-cell precursors ALL and Ph-like ALL - M. Konopleva</td>
</tr>
<tr>
<td>15.00 - 15.20</td>
<td>CAR-T Clinical Trials in ALL - F. Locatelli</td>
</tr>
<tr>
<td>15.20 - 15.40</td>
<td>Near future of CAR-T based approach in ALL - J. Ribera</td>
</tr>
<tr>
<td>15.40 - 16.00</td>
<td>Acute Myeloid Leukemia Clinical Session AML 1 - C. Cerchione, N. Daver, F. Ravandi</td>
</tr>
<tr>
<td>16.00 - 16.20</td>
<td>How we manage AML in daily practice in Europe - G. Martinelli</td>
</tr>
<tr>
<td>16.00 - 16.40</td>
<td>How we integrate immunotherapy and target-therapies in AML management - N. Daver</td>
</tr>
<tr>
<td>16.20 - 16.40</td>
<td>Optimizing FLT3 inhibitor use in AML in 2021 - N, Daver</td>
</tr>
<tr>
<td>16.40 - 17.00</td>
<td>Novel antibodies in AML: new target therapies are possible - F. Ravandi</td>
</tr>
<tr>
<td>17.00 - 17.20</td>
<td>Role of CPX-351 in AML - C. Cerchione</td>
</tr>
<tr>
<td>17.20 - 17.30</td>
<td>break</td>
</tr>
<tr>
<td>17.30 - 17.50</td>
<td>Clinical Session AML 1 - A. Isidori, M. Gottardi, A. Olivieri</td>
</tr>
<tr>
<td></td>
<td>Elderly AML: present and future - A. Isidori</td>
</tr>
</tbody>
</table>
17.50 - 18.10  How we manage BDPCN as new entity - L. Pagano
18.10 - 18.30  Role of allogenic transplant in AML - A. Olivieri
18.30 - 18.50  Role of maintenance in AML - M. Gottardi

Near future of Acute Leukemias - G. Martinelli, H. Kantarjian
19.30 - 19.50  Near future of Acute Leukemias in USA - H. Kantarjian
19.50 - 20.10  Near future of Acute Leukemias in Europe - G. Martinelli

Day 2  17 March 2021

Young session

Selected oral presentations with project presentations in different categories

1st Session: G. Simonetti, S. Galimberti, C. Quintarelli, C. Papayannidis, A. Ferrari, A. Ghelli

08.30 - 09.00  Biology of ALL 1
09.00 - 09.30  Biology of ALL 2
09.30 - 10.00  Biology of AML 1
10.00 - 10.30  Biology of AML 2
10.30 - 11.00  MRD monitoring of acute leukemias
11.00 - 11.15  break

11.15 - 11.45  Allogenic transplant
11.45 - 12.15 CAR-T
12.15 - 12.45 Elderly patients
12.45 - 13.15 Supportive care of acute leukemias
13.15 - 13.45 Selected categories of patients and real life trials

13.45-15.00 Symposium

3rd Session: H. Kantarjian, N. Daver, E. Jabbour, M. Konopleva, F. Ravandi, F. Locatelli, J. Ribera

15.00 - 15.30 Frontline treatment of AML
15.30 - 16.00 Relapsed/refractory treatment of AML
16.00 - 16.30 Frontline treatment of ALL
16.30 - 17.00 Relapsed/refractory treatment of ALL
17.00 - 17.30 Questions and answers and discussion for future papers

After presentations, all projects will be started to be defined, with their teams, objectives and timepoints

17.30 - 18.00 Conclusion and next steps
in association with

promoted by

supported by an unrestricted educational grant form
The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOitLEUKEMIA

You can use it on Facebook, Twitter, Instagram and LinkedIn

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly
@SOHOitLEUKEMIA
@SocietyofHemOnc
@IRSTufficiale
@MDAndersonNews
@pro_eventi
@GMartinelli2
@DottorClaudio

#SOHOitLEUKEMIA
in association with

Society of Hematologic Oncology

Promoted by

1ST SOHO ITALY
ACUTE LEUKEMIA
Clinical And Biological